Skip to main content
S&P 5007,568.92+0.36%DOW51,786.72-0.38%NASDAQ25,372.01+0.83%BTC$76,930.00-0.07%ETH$2,264.94+0.48%GOLD$3,934.20-0.16%OIL$96.70+0.63%
Smart Investors Daily
SID Premium
EV

NYSE · EVMN

Evommune, Inc.

Healthcare · Biotechnology

$6.01

Down-$0.07 (-1.16%)

Updated Nov 4, 2026, 12:58 AM

SID Score

3.0/10

Composite research score

Smart Money

—

Institutional and insider signal

Market cap
261.72M
P/E ratio
-21.13
Dividend yield
0.00%
52-week range
$4.94 – $29.07
Volume
728.85K
Avg. volume
205.5K

Price performance · EVMN

EVMN price history

1M range · 20 trading sessions · Daily adjusted prices

Prices through Nov 2, 2026

EVMN closed at $6.01 after 20 trading sessions, down 9.08% for the selected period.

Last close
$6.01
Period change
-9.08%
Period low
$5.10
Period high
$6.81
Daily close
View OHLC price history
EVMN OHLC price history, latest 40 sessions
DateOpenHighLowCloseVolume
Nov 2, 2026$6.75$6.815$5.89$6.01728.85K
Oct 30, 2026$6.65$6.84$6.29$6.73586.35K
Oct 29, 2026$6.38$7.18$6.28$6.811.15M
Oct 28, 2026$5.50$7.21$5.22$6.316.52M
Oct 27, 2026$5.13$5.26$4.96$5.161.3M
Oct 26, 2026$5.10$5.31$5.02$5.13322.22K
Oct 23, 2026$5.18$5.18$4.94$5.10280.83K
Oct 22, 2026$5.13$5.365$5.095$5.21255.76K
Oct 21, 2026$5.41$5.521$5.125$5.17383.39K
Oct 20, 2026$5.33$5.70$5.33$5.38382.46K
Oct 19, 2026$5.30$5.43$5.125$5.27422.78K
Oct 16, 2026$5.97$6.00$5.09$5.17986.71K
Oct 15, 2026$5.90$6.00$5.81$5.93579.09K
Oct 14, 2026$5.79$5.96$5.64$5.77574.84K
Oct 13, 2026$6.05$6.05$5.85$5.88805.29K
Oct 12, 2026$6.09$6.22$6.04$6.05384.15K
Oct 9, 2026$6.40$6.44$6.175$6.25557.96K
Oct 8, 2026$6.18$6.44$6.02$6.41691.98K
Oct 7, 2026$6.51$6.525$6.15$6.222.11M
Oct 6, 2026$6.67$6.67$6.08$6.611.01M

Latest EVMN news

The latest Smart Investors Daily articles mentioning EVMN.

Stock researchCompany · Overview

EVMN research

Overview

Company profile and research snapshot.

Company profile

Evommune Inc is a clinical-stage biotechnology company focused on creating new therapies aimed at key factors driving chronic inflammatory diseases. The initial clinical programs of the company target chronic spontaneous urticaria (CSU), atopic dermatitis (AD), and ulcerative colitis (UC). The pipeline products of the company include EVO756 and EVO301.

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
—
Average target
$39.33
Implied upside
—
Analysts
—
EVMN recent ratings
DateFirmRatingTarget
Oct 12, 2026UBSNeutral—
Sep 9, 2026Leerink PartnersOutperform—
Sep 9, 2026RBC CapitalOutperform—
Sep 9, 2026HC Wainwright & Co.Neutral—
Aug 26, 2026NeedhamBuy—
Open full forecast

News briefing

No generated briefing is available yet.

Yahoo · Oct 19, 2026

Migraine Market is Expected to Expand at 6% Growth Rate by 2036, Owing to the Development of Novel Mechanisms beyond CGRP, including PACAP-targeted Therapies, TRPA1 Antagonists, and Next-generation Neuromuscular Approaches | DelveInsight

The migraine market is expected to grow steadily over the forecast period (2026–2036) driven by the rising global prevalence of migraine, improving diagnosis rates, and increasing awareness of chronic and high-frequency migraine. In addition, the introduction of novel, differentiated therapies such as Elismetrep (Kallyope), Dysport (abobotulinumtoxinA; Ipsen), Xeomin (incobotulinumtoxinA; Merz Therapeutics GmbH), Bocunebart (AG09222; Lundbeck), EVO756 (Evommune), and others that move beyond trad

Yahoo · Oct 1, 2026

Evommune Presents Late-Breaking Phase 2a Proof-of-Concept Data Evaluating EVO301 in Atopic Dermatitis at European Academy of Dermatology and Venereology Congress

PALO ALTO, Calif. & NEW YORK, October 01, 2026--Evommune, Inc. (NYSE: EVMN) (the "Company" or "Evommune"), a clinical-stage biotechnology company developing innovative therapies that target key drivers of chronic inflammatory diseases, today shared additional data from its Phase 2a proof-of-concept trial of EVO301 in adults with moderate-to-severe atopic dermatitis (AD) during a late-breaking oral presentation at the European Academy of Dermatology and Venereology (EADV) 2026 Congress in Vienna,

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.

Featured By